Targeting Zfp36 to combat cardiac hypertrophy: Insights into ferroptosis pathways
Abstract Background Cardiac hypertrophy is a precursor to heart failure and represents a significant global cause of mortality, thereby necessitating timely and effective therapeutic interventions. Zinc finger protein 36 (Zfp36) is recognised as a critical regulator of ferroptosis; however, its role...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-03-01
|
| Series: | Clinical and Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ctm2.70247 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849328441096142848 |
|---|---|
| author | Mingyu Zhang Xiaoxiang Guan Zheng Dong Chenxu Yang Chao Xiong Wenzheng Cheng Aijing Shang Yaru Liu Xiaofei Guo Bowen Zhang Bo Zhang Saidi Jin Wenyi Qi Berezhnova Tatjana Alexandrovna Yuan Jiang Zhimin Du Chaoqian Xu |
| author_facet | Mingyu Zhang Xiaoxiang Guan Zheng Dong Chenxu Yang Chao Xiong Wenzheng Cheng Aijing Shang Yaru Liu Xiaofei Guo Bowen Zhang Bo Zhang Saidi Jin Wenyi Qi Berezhnova Tatjana Alexandrovna Yuan Jiang Zhimin Du Chaoqian Xu |
| author_sort | Mingyu Zhang |
| collection | DOAJ |
| description | Abstract Background Cardiac hypertrophy is a precursor to heart failure and represents a significant global cause of mortality, thereby necessitating timely and effective therapeutic interventions. Zinc finger protein 36 (Zfp36) is recognised as a critical regulator of ferroptosis; however, its role and underlying mechanisms in cardiac hypertrophy remain largely unexplored. This study aims to investigate the regulatory function of Zfp36 in ferroptosis within the context of cardiac hypertrophy. Methods and results Single‐cell sequencing analysis demonstrated a reduction in Zfp36 expression associated with cardiac hypertrophy. Zfp36 was observed to mitigate ferroptosis and reduce hypertrophic phenotypes in cardiomyocytes subjected to Angiotensin II (Ang II) and in myocardial tissues induced by transverse aortic constriction. The ferroptosis inhibitor Ferrostatin‐1 was shown to alleviate hypertrophy when co‐incubated with si‐Zfp36 and Ang II. Mechanistically, Zfp36 binds to the 3′ untranslated region (3′UTR) of Ythdc2 mRNA, facilitating its degradation. Ythdc2 subsequently binds to SLC7A11 mRNA, enhancing its decay, which leads to a reduction in glutathione (GSH) levels, thereby exacerbating ferroptosis and cardiac hypertrophy. Furthermore, overexpression of Ythdc2 reversed the protective effects conferred by Zfp36, while silencing of Ythdc2 counteracted the effects of Zfp36 knockdown. Conclusions This study elucidates the role of Zfp36 in cardiac hypertrophy, specifically detailing its modulatory mechanism via the Ythdc2/SLC7A11/GSH ferroptosis pathway. These insights lay the groundwork for innovative approaches to understanding the pathological mechanisms underlying cardiac hypertrophy and enhancing clinical interventions. Key points Zfp36 was initially demonstrated to attenuate cardiac hypertrophy through the inhibition of ferroptosis in cardiomyocytes, providing a new target for therapeutic strategies targeting ferroptosis. Zfp36 facilitated the degradation of Ythdc2 mRNA by binding to it, subsequently inhibiting Ythdc2‐mediated degradation of SLC7A11 mRNA, and maintaining GSH levels. This elucidates a previously unrecognized regulatory pathway in the context of cardiac hypertrophy. |
| format | Article |
| id | doaj-art-9d838d3c0b0f45fda796a5dc3e26931f |
| institution | Kabale University |
| issn | 2001-1326 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Medicine |
| spelling | doaj-art-9d838d3c0b0f45fda796a5dc3e26931f2025-08-20T03:47:36ZengWileyClinical and Translational Medicine2001-13262025-03-01153n/an/a10.1002/ctm2.70247Targeting Zfp36 to combat cardiac hypertrophy: Insights into ferroptosis pathwaysMingyu Zhang0Xiaoxiang Guan1Zheng Dong2Chenxu Yang3Chao Xiong4Wenzheng Cheng5Aijing Shang6Yaru Liu7Xiaofei Guo8Bowen Zhang9Bo Zhang10Saidi Jin11Wenyi Qi12Berezhnova Tatjana Alexandrovna13Yuan Jiang14Zhimin Du15Chaoqian Xu16State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD) Department of Pharmacology (State Key Labratoray ‐Province Key Laboratories of Biomedicine‐Pharmaceutics of China Key Laboratory of Cardiovascular Research, Ministry of Education) College of Pharmacy Harbin Medical University Harbin ChinaDepartment of Clinical Pharmacy the First Affiliated Hospital of Harbin Medical University Harbin ChinaState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD) Department of Pharmacology (State Key Labratoray ‐Province Key Laboratories of Biomedicine‐Pharmaceutics of China Key Laboratory of Cardiovascular Research, Ministry of Education) College of Pharmacy Harbin Medical University Harbin ChinaState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD) Department of Pharmacology (State Key Labratoray ‐Province Key Laboratories of Biomedicine‐Pharmaceutics of China Key Laboratory of Cardiovascular Research, Ministry of Education) College of Pharmacy Harbin Medical University Harbin ChinaState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD) Department of Pharmacology (State Key Labratoray ‐Province Key Laboratories of Biomedicine‐Pharmaceutics of China Key Laboratory of Cardiovascular Research, Ministry of Education) College of Pharmacy Harbin Medical University Harbin ChinaState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD) Department of Pharmacology (State Key Labratoray ‐Province Key Laboratories of Biomedicine‐Pharmaceutics of China Key Laboratory of Cardiovascular Research, Ministry of Education) College of Pharmacy Harbin Medical University Harbin ChinaState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD) Department of Pharmacology (State Key Labratoray ‐Province Key Laboratories of Biomedicine‐Pharmaceutics of China Key Laboratory of Cardiovascular Research, Ministry of Education) College of Pharmacy Harbin Medical University Harbin ChinaState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD) Department of Pharmacology (State Key Labratoray ‐Province Key Laboratories of Biomedicine‐Pharmaceutics of China Key Laboratory of Cardiovascular Research, Ministry of Education) College of Pharmacy Harbin Medical University Harbin ChinaState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD) Department of Pharmacology (State Key Labratoray ‐Province Key Laboratories of Biomedicine‐Pharmaceutics of China Key Laboratory of Cardiovascular Research, Ministry of Education) College of Pharmacy Harbin Medical University Harbin ChinaState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD) Department of Pharmacology (State Key Labratoray ‐Province Key Laboratories of Biomedicine‐Pharmaceutics of China Key Laboratory of Cardiovascular Research, Ministry of Education) College of Pharmacy Harbin Medical University Harbin ChinaState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD) Department of Pharmacology (State Key Labratoray ‐Province Key Laboratories of Biomedicine‐Pharmaceutics of China Key Laboratory of Cardiovascular Research, Ministry of Education) College of Pharmacy Harbin Medical University Harbin ChinaState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD) Department of Pharmacology (State Key Labratoray ‐Province Key Laboratories of Biomedicine‐Pharmaceutics of China Key Laboratory of Cardiovascular Research, Ministry of Education) College of Pharmacy Harbin Medical University Harbin ChinaState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD) Department of Pharmacology (State Key Labratoray ‐Province Key Laboratories of Biomedicine‐Pharmaceutics of China Key Laboratory of Cardiovascular Research, Ministry of Education) College of Pharmacy Harbin Medical University Harbin ChinaDepartment of Pharmacology, Voronezh State Medical University Named After N.N. Burdenko VoronezhState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD) Department of Pharmacology (State Key Labratoray ‐Province Key Laboratories of Biomedicine‐Pharmaceutics of China Key Laboratory of Cardiovascular Research, Ministry of Education) College of Pharmacy Harbin Medical University Harbin ChinaState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD) Department of Pharmacology (State Key Labratoray ‐Province Key Laboratories of Biomedicine‐Pharmaceutics of China Key Laboratory of Cardiovascular Research, Ministry of Education) College of Pharmacy Harbin Medical University Harbin ChinaState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD) Department of Pharmacology (State Key Labratoray ‐Province Key Laboratories of Biomedicine‐Pharmaceutics of China Key Laboratory of Cardiovascular Research, Ministry of Education) College of Pharmacy Harbin Medical University Harbin ChinaAbstract Background Cardiac hypertrophy is a precursor to heart failure and represents a significant global cause of mortality, thereby necessitating timely and effective therapeutic interventions. Zinc finger protein 36 (Zfp36) is recognised as a critical regulator of ferroptosis; however, its role and underlying mechanisms in cardiac hypertrophy remain largely unexplored. This study aims to investigate the regulatory function of Zfp36 in ferroptosis within the context of cardiac hypertrophy. Methods and results Single‐cell sequencing analysis demonstrated a reduction in Zfp36 expression associated with cardiac hypertrophy. Zfp36 was observed to mitigate ferroptosis and reduce hypertrophic phenotypes in cardiomyocytes subjected to Angiotensin II (Ang II) and in myocardial tissues induced by transverse aortic constriction. The ferroptosis inhibitor Ferrostatin‐1 was shown to alleviate hypertrophy when co‐incubated with si‐Zfp36 and Ang II. Mechanistically, Zfp36 binds to the 3′ untranslated region (3′UTR) of Ythdc2 mRNA, facilitating its degradation. Ythdc2 subsequently binds to SLC7A11 mRNA, enhancing its decay, which leads to a reduction in glutathione (GSH) levels, thereby exacerbating ferroptosis and cardiac hypertrophy. Furthermore, overexpression of Ythdc2 reversed the protective effects conferred by Zfp36, while silencing of Ythdc2 counteracted the effects of Zfp36 knockdown. Conclusions This study elucidates the role of Zfp36 in cardiac hypertrophy, specifically detailing its modulatory mechanism via the Ythdc2/SLC7A11/GSH ferroptosis pathway. These insights lay the groundwork for innovative approaches to understanding the pathological mechanisms underlying cardiac hypertrophy and enhancing clinical interventions. Key points Zfp36 was initially demonstrated to attenuate cardiac hypertrophy through the inhibition of ferroptosis in cardiomyocytes, providing a new target for therapeutic strategies targeting ferroptosis. Zfp36 facilitated the degradation of Ythdc2 mRNA by binding to it, subsequently inhibiting Ythdc2‐mediated degradation of SLC7A11 mRNA, and maintaining GSH levels. This elucidates a previously unrecognized regulatory pathway in the context of cardiac hypertrophy.https://doi.org/10.1002/ctm2.70247cardiac hypertrophyferroptosisRNA bindingYthdc2Zfp36 |
| spellingShingle | Mingyu Zhang Xiaoxiang Guan Zheng Dong Chenxu Yang Chao Xiong Wenzheng Cheng Aijing Shang Yaru Liu Xiaofei Guo Bowen Zhang Bo Zhang Saidi Jin Wenyi Qi Berezhnova Tatjana Alexandrovna Yuan Jiang Zhimin Du Chaoqian Xu Targeting Zfp36 to combat cardiac hypertrophy: Insights into ferroptosis pathways Clinical and Translational Medicine cardiac hypertrophy ferroptosis RNA binding Ythdc2 Zfp36 |
| title | Targeting Zfp36 to combat cardiac hypertrophy: Insights into ferroptosis pathways |
| title_full | Targeting Zfp36 to combat cardiac hypertrophy: Insights into ferroptosis pathways |
| title_fullStr | Targeting Zfp36 to combat cardiac hypertrophy: Insights into ferroptosis pathways |
| title_full_unstemmed | Targeting Zfp36 to combat cardiac hypertrophy: Insights into ferroptosis pathways |
| title_short | Targeting Zfp36 to combat cardiac hypertrophy: Insights into ferroptosis pathways |
| title_sort | targeting zfp36 to combat cardiac hypertrophy insights into ferroptosis pathways |
| topic | cardiac hypertrophy ferroptosis RNA binding Ythdc2 Zfp36 |
| url | https://doi.org/10.1002/ctm2.70247 |
| work_keys_str_mv | AT mingyuzhang targetingzfp36tocombatcardiachypertrophyinsightsintoferroptosispathways AT xiaoxiangguan targetingzfp36tocombatcardiachypertrophyinsightsintoferroptosispathways AT zhengdong targetingzfp36tocombatcardiachypertrophyinsightsintoferroptosispathways AT chenxuyang targetingzfp36tocombatcardiachypertrophyinsightsintoferroptosispathways AT chaoxiong targetingzfp36tocombatcardiachypertrophyinsightsintoferroptosispathways AT wenzhengcheng targetingzfp36tocombatcardiachypertrophyinsightsintoferroptosispathways AT aijingshang targetingzfp36tocombatcardiachypertrophyinsightsintoferroptosispathways AT yaruliu targetingzfp36tocombatcardiachypertrophyinsightsintoferroptosispathways AT xiaofeiguo targetingzfp36tocombatcardiachypertrophyinsightsintoferroptosispathways AT bowenzhang targetingzfp36tocombatcardiachypertrophyinsightsintoferroptosispathways AT bozhang targetingzfp36tocombatcardiachypertrophyinsightsintoferroptosispathways AT saidijin targetingzfp36tocombatcardiachypertrophyinsightsintoferroptosispathways AT wenyiqi targetingzfp36tocombatcardiachypertrophyinsightsintoferroptosispathways AT berezhnovatatjanaalexandrovna targetingzfp36tocombatcardiachypertrophyinsightsintoferroptosispathways AT yuanjiang targetingzfp36tocombatcardiachypertrophyinsightsintoferroptosispathways AT zhimindu targetingzfp36tocombatcardiachypertrophyinsightsintoferroptosispathways AT chaoqianxu targetingzfp36tocombatcardiachypertrophyinsightsintoferroptosispathways |